Welcome to our dedicated page for Jazz Pharmaceuticals Plc SEC filings (Ticker: JAZZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Jazz Pharmaceuticals plc (Nasdaq: JAZZ) SEC filings page on Stock Titan provides direct access to the company’s U.S. regulatory disclosures, alongside AI-assisted summaries to help interpret complex documents. Jazz, an Ireland-incorporated global biopharma company, files current and periodic reports as an issuer with ordinary shares listed on The Nasdaq Stock Market LLC under the symbol JAZZ.
Investors and researchers can review Form 8-K filings that report material events, including clinical trial milestones for products such as Ziihera (zanidatamab-hrii), financial results for specific quarters, executive and board changes, and legal settlements related to its sleep disorder and epilepsy franchises. These current reports often reference accompanying press releases that provide additional narrative detail on oncology and neuroscience developments.
Through this page, users can also locate references to quarterly and annual reports (Forms 10-Q and 10-K when available), which typically contain broader discussions of Jazz’s business, risk factors, pipeline, marketed medicines and financial condition. In addition, proxy materials and shareholder meeting results, such as votes on director elections and auditor appointments, are accessible for those tracking governance matters.
Stock Titan’s AI tools are designed to highlight key points from lengthy filings, helping users quickly identify sections related to oncology programs, neuroscience assets, royalty and settlement agreements, or capital markets activity. Where applicable, investors can also review insider-related filings such as Forms 3, 4 and 5 to monitor transactions in JAZZ ordinary shares by directors and officers, as reported to the SEC.
By combining real-time EDGAR updates with AI-generated overviews, this page offers a practical way to follow how Jazz Pharmaceuticals documents its clinical progress, corporate actions and financial reporting obligations in the U.S. regulatory framework.
Jazz Pharmaceuticals plc executive Mary Elizabeth Henderson reported an equity award vesting. On January 16, 2026, she acquired 10,116 ordinary shares of Jazz Pharmaceuticals at a stated price of $0.0 per share. These shares relate to performance share awards originally granted on March 3, 2023, with the performance-based vesting conditions certified as achieved on January 16, 2026.
Following this transaction, Henderson beneficially owns 29,624 ordinary shares in total, held directly. She serves as SVP, Technical Operations at Jazz Pharmaceuticals. The Form 4 indicates this is a non-derivative acquisition tied to prior performance awards rather than an open-market purchase.
Jazz Pharmaceuticals executive Patricia Carr, who serves as SVP and Chief Accounting Officer, reported an acquisition of company stock. On January 16, 2026, she acquired 2,370 ordinary shares at a price of $0.0 per share. These shares will be delivered under performance share awards originally granted on March 3, 2023, after the company certified that the performance-based vesting requirements were satisfied on January 16, 2026. Following this award vesting, Carr now directly beneficially owns 9,382 ordinary shares of Jazz Pharmaceuticals.
Jazz Pharmaceuticals’ EVP & Chief Legal Officer Neena M. Patil reported equity compensation activity in the company’s ordinary shares. On
On the same date, 3,275 ordinary shares were disposed of at
Jazz Pharmaceuticals executive Samantha Pearce reported equity award activity in Jazz (JAZZ) shares. On January 16, 2026, she acquired 3,637 ordinary shares at a price of $0.0, delivered under performance share awards originally granted on March 3, 2023, after performance-based vesting requirements were certified as satisfied on that date.
Also on January 16, 2026, 1,599 ordinary shares were withheld at $171.16 per share to cover her tax obligations arising from the vesting and distribution of those performance share awards. After these transactions, she directly owned 42,993 ordinary shares of Jazz Pharmaceuticals. A footnote notes that she had previously acquired 140 ordinary shares under a Section 423 employee stock purchase plan on November 28, 2025.
Jazz Pharmaceuticals executive Robert Iannone reported equity compensation activity involving the company’s ordinary shares. On January 16, 2026, he received 11,699 ordinary shares at a price of $0.00 per share, delivered upon the vesting of performance share awards that were granted on March 3, 2023 after performance was certified. On the same date, 4,140 ordinary shares were withheld at $171.16 per share to cover his tax obligations related to the vesting and distribution of those awards.
Following these transactions, Iannone directly beneficially owned 80,258 ordinary shares of Jazz Pharmaceuticals. The filing also notes that he previously acquired 71 ordinary shares under a Section 423 employee stock purchase plan on November 28, 2025.
Jazz Pharmaceuticals plc President & CEO Renee D. Gala reported changes in her holdings of ordinary shares tied to performance-based equity awards. On January 16, 2026, she received 12,741 ordinary shares at a price of $0.00 per share, delivered upon the vesting of performance share awards that were originally granted on March 3, 2023, after performance was certified as achieved.
On the same date, 5,371 ordinary shares were withheld at a price of $171.16 per share to cover her tax obligations related to the vesting and distribution of these performance share awards. Following these transactions, Gala directly beneficially owns 115,230 ordinary shares of Jazz Pharmaceuticals.
Jazz Pharmaceuticals plc director Bruce C. Cozadd reported equity compensation and related tax withholding transactions in the company’s ordinary shares. On January 16, 2026, he received 35,917 ordinary shares at $0.0 per share, delivered under performance share awards that were originally granted on March 3, 2023 and certified as having met their performance-based vesting requirements on that date.
Also on January 16, 2026, 17,453 ordinary shares were disposed of at a price of $171.16 per share, with the filing explaining that these shares were withheld from the vesting and distribution of the performance share awards to satisfy his tax obligations. Following these transactions, Cozadd directly beneficially owned 411,796 ordinary shares of Jazz Pharmaceuticals.
Jazz Pharmaceuticals plc reported that it plans to present a corporate overview and financial update at the J.P. Morgan Healthcare Conference in San Francisco on January 13, 2026. In this presentation, the company states that it expects to meet its previously announced total revenue guidance range for the year ended December 31, 2025. Jazz also outlines expectations for revenue contributions in 2025 from key products Xywav, Epidiolex and Modeyso. The related presentation slides are provided as Exhibit 99.1.
Jazz Pharmaceuticals plc director Patrick Enright reported a transfer of 5,000 Ordinary Shares on 08/18/2025. The Form 4 shows this was a code J transaction, with a footnote explaining the shares were transferred to a former spouse without any payment as part of a comprehensive division of marital assets. After this transfer, Enright beneficially owned 21,379 Ordinary Shares, held directly.
Jazz Pharmaceuticals plc disclosed that senior vice president of technical operations Mary Elizabeth Henderson sold 2,238 ordinary shares on 12/09/2025. The transaction was reported with code "S" for an open-market or private sale at a weighted average price of $169.511, with individual trades executed between $169.00 and $169.82. Following these sales, she directly beneficially owns 19,508 ordinary shares of Jazz Pharmaceuticals.
FAQ
What is the current stock price of Jazz Pharmaceuticals Plc (JAZZ)?
What is the market cap of Jazz Pharmaceuticals Plc (JAZZ)?
